XML 33 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
12 Months Ended 101 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
OPERATING ACTIVITIES      
Net loss $ (4,053) $ (9,711) $ (150,445)
Non cash items:      
Deferred tax expense 0 0 770
Depreciation and amortization 29 117 3,971
Non-cash stock-based compensation 107 159 4,931
Gain on sale of bone device business 0 0 (2,298)
In-process research and development 0 0 34,311
Change in other operating items:      
Interest, income taxes and other current assets 375 (115) 1,325
Accounts payable 156 (169) (738)
Accrued liabilities 19 (871) (2,956)
Cash flows used in operating activities (3,367) (10,590) (111,129)
INVESTING ACTIVITIES      
Expenditures for furniture and equipment, net 0 (19) (1,044)
Proceeds from sale of assets 172 0 7,172
Cash paid for assets of AzERx/CBI 0 0 (4,058)
Cash paid for patent rights (378) 0 (1,028)
Purchases of investments 0 0 (282,538)
Maturities of investments 0 0 340,476
Cash flows provided by (used in) investing activities (206) (19) 58,980
FINANCING ACTIVITIES      
Net proceeds from stock option exercises 0 0 4,612
Net proceeds from sale of stock 0 0 3,376
Common stock purchases 0 0 (1,041)
Cash flows provided by financing activities 0 0 6,947
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (3,573) (10,609) (45,202)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 13,778 24,387 55,407
CASH AND CASH EQUIVALENTS, END OF PERIOD 10,205 13,778 10,205
Supplemental Disclosure of Non-Cash Investing Activities - LipimetiX/AzERx/CBI Acquisitions:      
Cash paid 0 0 4,058
Lipimetix [Member]
     
INVESTING ACTIVITIES      
Cash paid for assets of AzERx/CBI (378)   (4,436)
Supplemental Disclosure of Non-Cash Investing Activities - LipimetiX/AzERx/CBI Acquisitions:      
Current assets acquired 0   29
Patent rights acquired 1,045   3,187
Liabilities acquired, and accrued acquisition costs 0   (457)
Original investment reversal 0   (750)
In-process research and development acquired 0   34,311
Noncontrolling interest (667)   (667)
Common stock issued for acquisition 0   (31,217)
Cash paid $ 378   $ 4,436